A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

The global health burden for hepatitis C virus (HCV) remains high, despite available effective treatments. To eliminate HCV, a prophylactic vaccine is needed. One major challenge in the development of a vaccine is the genetic diversity of the virus, with 7 major genotypes and many subtypes. A global...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Janelle, Freedman, Holly, Logan, Michael, Wong, Jason Alexander Ji-Xhin, Hockman, Darren, Chen, Chao, He, Jianqi, Beard, Michael R., Eyre, Nicholas S., Baumert, Thomas F., Tyrrell, D. Lorne, Law, John L. M., Houghton, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819942/
https://www.ncbi.nlm.nih.gov/pubmed/31462563
http://dx.doi.org/10.1128/JVI.00810-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819942/
https://www.ncbi.nlm.nih.gov/pubmed/31462563
http://dx.doi.org/10.1128/JVI.00810-19

Ejemplares similares